Zhou Maotian, Zhang Xue, Yan Huan, Xing Lili, Tao Yi, Shen Liang
DMPK, Lab Testing Division, WuXi AppTec, Suzhou, China.
DMPK, Lab Testing Division, WuXi AppTec, Shanghai, China.
Bioanalysis. 2024 Dec-Dec;16(23-24):1279-1294. doi: 10.1080/17576180.2024.2437418. Epub 2024 Dec 14.
Over the past years, gene therapeutics have held great promise for treating many inherited and acquired diseases. The increasing number of approved gene therapeutics and developing clinical pipelines demonstrate the potential to treat diseases by modifying their genetic blueprints in vivo. Compared with conventional treatments targeting proteins rather than underlying causes, gene therapeutics can achieve enduring or curative effects via gene activation, inhibition, and editing. However, the delivery of DNA/RNA to the target cell to alter the gene expression is a complex process that involves, crossing numerous barriers in both the extracellular and intracellular environment. Generally, the delivery strategies can be divided into viral-based and non-viral-based vectors. This review summarizes various bioanalysis strategies that support the non-virus-based gene therapeutics research, including pharmacokinetics (PK)/toxicokinetics (TK), biodistribution, immunogenicity evaluations for the gene cargo, vector, and possible expressed protein, and highlights the challenges and future perspectives of bioanalysis strategies in non-virus-based gene therapeutics. This review may provide new insights and directions for the development of emerging bioanalytical methods, offering technical support and a research foundation for innovative gene therapy treatments.
在过去几年中,基因疗法在治疗多种遗传性和获得性疾病方面展现出了巨大的前景。越来越多获批的基因疗法以及不断发展的临床研发管线表明,通过在体内修改疾病的基因蓝图来治疗疾病具有潜力。与针对蛋白质而非根本病因的传统治疗方法相比,基因疗法可以通过基因激活、抑制和编辑实现持久或治愈性效果。然而,将DNA/RNA递送至靶细胞以改变基因表达是一个复杂的过程,这涉及跨越细胞外和细胞内环境中的众多障碍。一般来说,递送策略可分为基于病毒的载体和基于非病毒的载体。本综述总结了支持非病毒基因疗法研究的各种生物分析策略,包括药代动力学(PK)/毒代动力学(TK)、生物分布、对基因载体、载体以及可能表达的蛋白质的免疫原性评估,并强调了非病毒基因疗法中生物分析策略面临的挑战和未来展望。本综述可能为新兴生物分析方法的发展提供新的见解和方向,为创新基因治疗提供技术支持和研究基础。